Mobile PSA : A Novel Telehealth Tool for Prostate Cancer Follow-Up
| Autor: | Mika P. Matikainen, Robin Bergroth, Antti Rannikko |
|---|---|
| Přispěvatelé: | Urologian yksikkö, University of Helsinki, Helsinki University Hospital Area, HUS Abdominal Center, Clinicum, Department of Surgery, Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Telemedicine 020205 medical informatics Urology medicine.medical_treatment ANTIGEN 3122 Cancers 02 engineering and technology Telehealth urologic and male genital diseases 03 medical and health sciences Prostate cancer 0302 clinical medicine Health care 0202 electrical engineering electronic engineering information engineering medicine eHealth Brief Correspondence Intensive care medicine RC254-282 business.industry Prostatectomy Follow-up Neoplasms. Tumors. Oncology. Including cancer and carcinogens COVID-19 MEN medicine.disease 3126 Surgery anesthesiology intensive care radiology Diseases of the genitourinary system. Urology Prostate-specific antigen 3. Good health Radiation therapy REMINDERS 030220 oncology & carcinogenesis RC870-923 business |
| Zdroj: | European Urology Open Science European Urology Open Science, Vol 28, Iss, Pp 43-46 (2021) |
| Popis: | The prevalence of prostate cancer (PCa) is increasing. As the prognosis of PCa continues to improve, the increasing follow-up requirements after radical prosta-tectomy or radiotherapy puts significant pressure on health care systems. Follow-up is typically conducted by treating urologists, specialized nurses, or general practitioners. Despite the increase in patient numbers, resources are not likely to increase in proportion. Furthermore, the ongoing COVID-19 pandemic has led to a paradigm shift in our thinking towards telehealth solutions, primarily to avoid or limit physical contact and to spare resources. Here we report our novel telehealth solution for PCa follow-up, called Mobile PSA. Currently, more than 4500 PCa patients have been using Mobile PSA follow-up in our center. Mobile PSA can increase follow-up accuracy, as all biochemical relapses will be detected in a timely manner, can significantly reduce delays in reporting prostate-specific antigen results to patients, and can significantly reduce costs. Patient summary: We assessed a new telehealth information system for prostate cancer follow-up that does not use an app. More than 4500 prostate cancer patients in our center have used this system, called Mobile PSA, for follow-up. The system significantly reduces delays in reporting prostate-specific antigen (PSA) test results to patients, increases the accuracy of detecting recurrence of elevated PSA, and reduces costs. (c) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creati-vecommons.org/licenses/by-nc-nd/4.0/). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|